Allogene Therapeutics, Inc. (ALLO)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Allogene Therapeutics, Inc. reported revenue of $0, down 100.0% from the prior year. The company ran a net loss. It held $415.90M in total assets against $123.36M in total liabilities.
Key ratios (FY2025)
-65.3%
Return on equity
-100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22.0K | $95.0K | $156.0K | $114.09M | $0 | $0 | — | — |
| Operating Income | -$209.31M | -$273.20M | -$327.74M | -$335.54M | -$180.19M | -$258.24M | -$202.01M | -$192.84M | — |
| Net Income | -$190.89M | -$257.59M | -$327.26M | -$340.41M | -$182.05M | -$316.38M | -$184.59M | -$211.50M | — |
| EPS (Diluted) | $-0.87 | $-1.32 | $-2.09 | $-2.38 | $-1.34 | $-2.63 | $-1.83 | — | — |
| Total Assets | $415.90M | $548.71M | $642.84M | $821.58M | $1.05B | $1.23B | $717.80M | $773.86M | — |
| Total Liabilities | $123.36M | $126.53M | $130.60M | $154.70M | $125.63M | $148.21M | $88.78M | $70.69M | $2.0K |
| Shareholders' Equity | $292.54M | $422.18M | $512.23M | $666.88M | $925.20M | $1.01B | $629.02M | $703.16M | -$2.0K |
| Cash & Equivalents | $51.69M | $75.22M | $83.16M | $61.90M | $173.31M | $183.35M | $175.13M | $92.43M | — |
| Operating Cash Flow | -$149.25M | -$200.30M | -$237.73M | -$220.52M | -$184.81M | -$115.09M | -$137.35M | -$44.65M | — |
| Capital Expenditures | $386.0K | $694.0K | $1.52M | $5.19M | $21.45M | $65.96M | $50.79M | $3.23M | — |
| Shares Outstanding | 229.41M | 212.21M | 168.64M | 144.44M | 142.62M | 140.47M | 124.27M | 121.48M | 26.25M |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |